Stock Events

Stock Events

Geron 

$1.1700
152
+$0.04+3.54% 11:44 Today

Statistics

Day High
1.13
Day Low
1.12
52W High
2.01
52W Low
1.04
Volume
157,899
Avg. Volume
-
Mkt Cap
725.99M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 4Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.04
-0.03
-0.02
-0.01
Expected EPS
-0.008
Actual EPS
N/A

Financials

-45.41%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
183.88MRevenue
-83.5MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GERN. It's not an investment recommendation.
NVIDIA
26
NVDA
Amazon
20
AMZN
Microsoft
17
MSFT
Apple
16
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap217.9B
Amgen is a biotechnology company focused on developing novel therapies, including for hematologic malignancies, which competes with Geron's focus on blood cancers.
Johnson & Johnson
JNJ
Mkt Cap617.01B
Johnson & Johnson, through its pharmaceutical segment Janssen, develops treatments for various cancers, directly competing with Geron's cancer therapies.
Bristol-Myers Squibb
BMY
Mkt Cap124.91B
Bristol Myers Squibb offers a wide range of cancer treatments, including those for hematologic cancers, making it a direct competitor to Geron.
Novartis
NVS
Mkt Cap268B
Novartis is a global healthcare company with a significant presence in oncology, including research in treatments for blood cancers, competing with Geron's development focus.
Pfizer
PFE
Mkt Cap158.45B
Pfizer has a diverse oncology portfolio, including therapies for breast and hematologic cancers, positioning it as a competitor to Geron.
Abbvie
ABBV
Mkt Cap464.43B
AbbVie, with its acquisition of Pharmacyclics, has expanded its oncology portfolio, including treatments for hematologic malignancies, competing with Geron's therapeutic area.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences, through its acquisition of Kite Pharma, has become a leader in cell therapies for cancer, including hematologic malignancies, competing with Geron's focus.
Merck
MRK
Mkt Cap356.01B
Merck & Co. is involved in the development of cancer treatments, including immunotherapies that could be used in treating hematologic cancers, making it a competitor to Geron.
Rogers
ROG
Mkt Cap2.86B
Roche, with its strong focus on oncology and a broad portfolio of cancer treatments, including for blood cancers, competes with Geron in the oncology space.

About

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Show More
CEO
Harout Semerjian
Employees
258
Country
United States
ISIN
US3741631036
WKN
000902213

Listings

MI
IT
1GERN.MI
MU
DE
GON.MU
STU
DE
GON.STU
BOATS
BOATS
GERN.BOATS

0 Comments

Share your thoughts

FAQs

What is Geron stock price today?▼
The current price of GERN is $1.17 USD — it has increased by +3.54% in the past 24 hours. Watch Geron stock price performance more closely on the chart.
What is Geron stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Geron stocks are traded under the ticker GERN.
Is Geron stock price growing?▼
GERN stock has fallen by -3.42% compared to the previous week, the month change is a -8.87% fall, over the last year Geron has showed a -7.38% decrease.
What is Geron market cap?▼
Today Geron has the market capitalization of 725.99M
When is the next Geron earnings date?▼
Geron is going to release the next earnings report on November 4, 2026.
What were Geron earnings last quarter?▼
GERN earnings for the last quarter are -0.02 USD per share, whereas the estimation was -0.01 USD resulting in a -125.23% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Geron revenue for the last year?▼
Geron revenue for the last year amounts to 183.88M USD.
What is Geron net income for the last year?▼
GERN net income for the last year is -83.5M USD.
How many employees does Geron have?▼
As of October 23, 2026, the company has 258 employees.
In which sector is Geron located?▼
Geron operates in the Health & Wellness sector.
When did Geron complete a stock split?▼
Geron has not had any recent stock splits.
Where is Geron headquartered?▼
Geron is headquartered in FOSTER CITY, United States.